Moreover, anti-angiogenic therapy may lead to the onset of hypoxia, resulting in the activation of HIF1a in tumor cells with a consequence of tumor cell adaptation to hypoxia and the promotion of tumor angiogenesis (Bergers and Hanahan, 2010). Here, HIF1A is linked to neoplasm.